Gunnarsson G, Hammer S M
Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, USA.
Hosp Pract (1995). 1995 Aug;30 Suppl 1:5-22.
Despite hopes for attack of multiple viral targets, the licensed agents now in use are all of one type: the nucleoside analogue reverse transcriptase inhibitors, of which four, including zidovudine, are available, with a fifth likely to follow. Clinicians and patients are still struggling to learn how best to employ them; but even now, the available trial results can be distilled into rational management plans.
尽管人们寄希望于攻击多个病毒靶点，但目前使用的已获许可的药物均为同一类型：核苷类似物逆转录酶抑制剂，其中包括齐多夫定在内有四种药物可供使用，第五种药物可能随后推出。临床医生和患者仍在努力学习如何最佳地使用这些药物；但即便如此，现有的试验结果仍可提炼为合理的管理方案。
